Bolt Biotherapeutics (BOLT NASDAQ) stock market data APIs
$4.5298
0.2(4.4%)
as of November 7, 2025
Try our APIs with
free plan!
Bolt Biotherapeutics Financial Data Overview
Price chart is built with
Anychart
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Prev. Close
4.5298
Open
4.7322
High
4.7735
Low
4.3771
52 wk Range
4.42-13.206
Market Cap
8 733 K
Shares Outstanding
1 919 K
Revenue
4 167 K
EPS
-4.46
Beta
0.924
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bolt Biotherapeutics data using free add-ons & libraries
Get Bolt Biotherapeutics Fundamental Data
Bolt Biotherapeutics Fundamental data includes:
- Net Revenue: 4 167 K
- EBITDA: -51 825 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bolt Biotherapeutics News
New
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
Bolt Biotherapeutics, Inc. (BOLT) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consens...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index shedding 0.4% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 0...
Bolt Biotherapeutics GAAP EPS of -$4.46 beats by $1.99, revenue of $1.8M beats by $0.98M
* Bolt Biotherapeutics press release [https://seekingalpha.com/pr/20201891-bolt-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:BOLT [https://seekingalph...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
